07:00 , Oct 2, 2014 |  BC Innovations  |  Strategy

Progressive thinking in MS

Despite the slew of treatments that have entered the market in the last few years for relapsing-remitting multiple sclerosis, there have been few advances in the progressive form of the disease, largely because there is...
08:00 , Feb 13, 2014 |  BC Innovations  |  Targets & Mechanisms

A RIPping target in Gaucher's disease

Enzyme-replacement therapies are highly effective for most patients with Gaucher's disease but do little for those with the neurological childhood forms of the disease. Now, an Israeli and U.K. team has unlocked the mechanism of...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Brazaves miglustat regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Actelion's Brazaves miglustat to treat Niemann-Pick type C disease. Miglustat is marketed as Zavesca for the indication in 42 countries including Australia, Brazil, Canada, Russia, South...
08:00 , Nov 7, 2011 |  BioCentury  |  Emerging Company Profile

Orphazyme: One for all

Drug development for lysosomal storage disorders has largely centered on enzyme replacement therapies, which yield one drug per disease. Orphazyme ApS believes its recombinant heat shock protein 70 (Hsp70) and small molecules that induce heat...
07:00 , Sep 1, 2011 |  BC Innovations  |  Targets & Mechanisms

Difficile defense

A team led by The University of Texas Medical Branch has identified the nitrosylation of Clostridium difficile toxins as a host defense mechanism that reduces cellular damage caused by the pathogen . 1 The researchers...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Tracleer bosentan regulatory update

FDA issued a warning letter to Actelion after an inspection revealed that the company failed to comply with postmarketing safety reporting requirements for 3 drugs. FDA said the company failed to report serious and unexpected...
07:00 , Sep 6, 2010 |  BioCentury  |  Strategy

Laying siege

sanofi-aventis Group made clear in its conference call last week that it's in no hurry to complete its proposed acquisition of Genzyme Corp. - with the obvious implication that time is on its side. If...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Zavesca miglustat regulatory update

Health Canada approved Actelion's Zavesca miglustat to treat Niemann-Pick type C disease. Zavesca is also approved in Australia, Brazil, Russia, South Korea and the EU in the indication. The oral N-butyldeoxynojirimycin glucosyltransferase inhibitor is approved...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

Zavesca miglustat regulatory update

FDA issued a complete response letter for an sNDA from Actelion for Zavesca miglustat to treat progressive neurological manifestations in patients with Niemann-Pick type C disease. The agency asked Actelion to provide additional preclinical and...
02:10 , Mar 10, 2010 |  BC Extra  |  Company News

Zavesca receives complete response

FDA issued a complete response letter for an sNDA from Actelion Ltd. (SIX:ATLN) for Zavesca miglustat to treat progressive neurological manifestations in patients with Niemann-Pick type C disease. The agency asked Actelion to provide additional...